

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/034,950
				Filing Date	December 26, 2001; Conf. No. 9344
				First Named Inventor	Bhami Shenoy et al.
				Art Unit	1656
				Examiner Name	Suzanne Marie Noakes
Sheet	1	of	1	Attorney Docket Number	VPI/00-08 RCE US


FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ¹ - Number ² - Kind Code ³				
		WO 00/77281	12/21/2000	PCT		

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
		Chayen et al., Recent Advances in Methodology for Crystallization of Biological Macromolecules," <i>Journal of Crystal Growth</i> , 198-199:649-655 (1999).	
		Hainsworth et al., "Monoclonal antibody therapy in lymphoid malignancies," 5(5):376-384 (2000).	
		McPherson et al., "Crystallization of Macromolecules: General Principles," <i>Methods in Enzymology</i> 114:112-120 (1985).	
		Saphire et al., "Crystallization and Preliminary Structure Determination of an Intact Human Immunoglobulin, b12: An Antibody that Broadly Neutralizes Primary Isolates of HIV-1," <i>Acta Cryst.</i> , D57:168-171 (2001).	
		Schwarz et al., "Anti-TNF-Alpha Therapy as Clinical Intervention for Periprosthetic Osteolysis," <i>Arthritis Research</i> , 2:165-168 (2000).	
		Van Assche et al., "Anti-TNF agents in Crohn's Disease," <i>Expert Opinion in Investigational Drugs</i> , 9(1):103-111 (2000)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/034,950
				Filing Date	December 26, 2001; Conf. No. 9344
				First Named Inventor	Bhami Shenoy et al.
				Art Unit	1656
				Examiner Name	Suzanne Marie Noakes
Sheet	1	of	1	Attorney Docket Number	VPI/00-08 RCE US

FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ¹ - Number ² - Kind Code ³				
		WO 00/77281	12/21/2000	PCT		

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published	T ⁶
		Chayen et al., Recent Advances in Methodology for Crystallization of Biological Macromolecules," <i>Journal of Crystal Growth</i> , 198-199:649-655 (1999).	
		Hainsworth et al., "Monoclonal antibody therapy in lymphoid malignancies," 5(5):376-384 (2000).	
		McPherson et al., "Crystallization of Macromolecules: General Principles," <i>Methods in Enzymology</i> 114:112-120 (1985).	
		Saphire et al., "Crystallization and Preliminary Structure Determination of an Intact Human Immunoglobulin, b12: An Antibody that Broadly Neutralizes Primary Isolates of HIV-1," <i>Acta Cryst.</i> , D57:168-171 (2001).	
		Schwarz et al., "Anti-TNF-Alpha Therapy as Clinical Intervention for Periprosthetic Osteolysis," <i>Arthritis Research</i> , 2:165-168 (2000).	
		Van Assche et al., "Anti-TNF agents in Crohn's Disease," <i>Expert Opinion in Investigational Drugs</i> , 9(1):103-111 (2000)	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.